Changes of Monoamine Transmitters in the Gastrointestinal Tract and Gastrointestinal Glial Cells of MPTP Induced Parkinson's Disease Mice

doi:10.19803/j.1672-8629.2021.04.05

Abstract

Abstract: Objective To explore the changes of monoamine neurotransmitters and enteric glial cells (EGC) in the gastrointestinal tract of Parkinson’s disease (PD) mice. Methods The PD models of wild-type mice and A53T transgenic mice were made by gaving mice intraperitoneal injections of probenecid, followed by subcutaneous injections of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). The changes of neurotransmitters in the gastrointestinal tract of mice were detected by high-performance liquid chromatography (HPLC) and the changes of gastrointestinal glial cells were evaluated by immunofluorescence. Results HPLC results showed that MPTP reduced the level of norepinephrine (NE) and increased the level of dihydroxy phenylacetaldehyde (DOPAL) of toxic metabolite of dopamine (DA). but it was no significant effect on the transmitter levels of DA and its metabolites which are dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA). The results of immunofluorescence showed the expression of glial fibrillary acidic protein (GFAP) in intestinal glial cells increasing. Conclusion MPTP can induce the decrease of NE neurotransmitter levels in the peripheral gastrointestinal tract and the activation of gastrointestinal glial cells, which may be related to gastrointestinal dysfunction in the early stage of PD.

Key words: Parkinson's disease, MPTP, gastrointestinal tract, monoamine transmitter, enteric glial cells

CLC Number:

R994.1

WEN Lu, WANG Shuo, ZHANG Chenglu, CHEN Naihong, YUAN Yuhe. Changes of Monoamine Transmitters in the Gastrointestinal Tract and Gastrointestinal Glial Cells of MPTP Induced Parkinson's Disease Mice[J]. Chinese Journal of Pharmacovigilance, 2021, 18(4): 320-323.

References

[1] Oertel W, Schulz JB.Current and experimental treatments of parkinson disease: A guide for neuroscientists[J]. Journal of Neurochemistry, 2016, 139(Suppl 1): 325-337.
[2] Heiko B, Kelly DT, Udo R, et al.Staging of brain pathology related to sporadic parkinson's disease[J]. Neurobiology of Aging, 2003, 24(2): 197-211.
[3] Heiko B, Rob AIV, Jürgen B, et al.Gastric α-synuclein immunoreactive inclusions in meissner's and auerbach's plexuses in cases staged for parkinson's disease-related brain pathology[J]. Neuroscience Letters, 2006, 396(1): 67-72.
[4] Derkinderen P, Rouaud T, Lebouvier T, et al.Parkinson disease: the enteric nervous system spills its guts[J]. Neurology, 2011, 77( 19): 1761-1767.
[5] Mittal R, Debs LH, Patel AP, et al.Neurotransmitters: the critical modulators regulating gut-brain axis[J]. Journal of Cellular Physiology, 2017, 232(9): 2359-2372.
[6] Jackson-Lewis V, Przedborski S.Protocol for the MPTP mouse model of parkinson's disease[J]. Nature Protocols, 2007, 2(1): 141-151.
[7] Lydén-Sokolowski A, Larsson BS, Lindquist NG.Disposition of 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in mice before and after monoamine oxidase and catecholamine reuptake inhibition[J]. Pharmacology & Toxicology, 1988, 63(2): 75-80.
[8] Vanderlei de AL, Lucas AN, David E, et al. Role of parkinson's disease-linked mutations and N-terminal acetylation on the oligomerization of α-synuclein induced by DOPAL[J]. ACS Chemical Neuroscience, 2019, 10(1): 690-703.
[9] Tache Y, Martinez V, Million M, et al.Stress and the gastrointestinal tract iii. stress-related alterations of gut motor function[J]. American Journal of Physiology, 2001, 280(2): G173-G177.
[10] Natale G, Pasquali L, Ruggieri S, et al.Parkinson's disease and the gut: a well known clinical association in need of an effective cure and explanation[J]. Neurogastroenterology & Motility, 2010, 20(7): 741-749.
[11] Gulbransen BD, Sharkey KA.Novel functional roles for enteric glia in the gastrointestinal tract[J]. Nature Reviews Gastroenterology & Hepatology, 2012, 9(11): 625-32.
[12] Clairembault T, Kamphuis W, Leclair-Visonneau L, et al.Enteric GFAP expression and phosphorylation in parkinson's disease[J]. Journal of Neurochemistry, 2014, 130(6): 805-815.
[13] CorbilléAG, Clairembault T, Coron E, et al. What a gastroin-testinal biopsy can tell us about Parkinson's disease?[J]. Neuro- gastroenterology & Motility, 2016, 28(7): 966-974.
[14] Dinan TG, Cryan JF.The microbiome-gut-brain axis in health and disease[J]. Gastroenterology Clinics of North America, 2017, 46(1): 77-89.
[15] Valentina C, Maria G.Microbiome-gut-brain axis and toll-like receptors in parkinson's disease[J]. International Journal of Molecular Sciences, 2018, 19(6): 1689.